Posted: Wed Mar 11, 2009 9:20 am Post subject: Catalent Analytical Team Member to be Published in Journal
Catalent Analytical Team Member to be Published in Journal of Pharmaceutical Research
Released on: March 11, 2009, 12:36 am
Author: Dan Dunlop / Jennings
Research Triangle Park, N.C. - March 10, 2009 Ė Catalent Pharma Solutions, a worldwide leading provider of advanced technologies for pharmaceutical, biotechnology and consumer health companies, will be featured in the upcoming April edition of Journal of Pharmaceutical Research. Stephen P. Mayock, a member of Catalentís analytical team, was a major contributor to the article that conveys the present challenges and future relevance of the science of USP 1 and 2 dissolution.
The article begins with the scientific origins of the dissolution test and discusses the roles of dissolution in product development, consistent batch manufacture and stability testing. It also reviews the ultimate role of dissolution testing where the end results correlate to in vivo results. Other topics that are covered in the article include the mechanical calibration versus performance testing, variability and hydrodynamics of USP Apparatus 1 and 2 and new initiatives in the industry such as quality by design, process analytical technology and design of experiment.
Mayock is the senior manager in Catalentís Stability and Analytical Services Group. Catalentís analytical team is part of its Respiratory, Analytical and Biotechnology group, with sites in the Research Triangle Park, N.C., San Diego C.A., and Middleton, W.I. Mayock joins fellow authors Vivian Gray, Gregg Kelly, Min Xia, Chris Butler and Saji Thomas. The article has been available online to subscribers since Jan. 25, 2009, and the print version will be available in the April edition.
About the Journal of Pharmaceutical Research
Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, presents papers that describe innovative research spanning the entire spectrum of drug discovery, development, evaluation, and regulatory approval. Small drug molecules, biotechnology products including genes, peptides, proteins and vaccines, and genetically engineered cells are an integral part of papers published.
Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer health companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,500 at more than 30 facilities worldwide and generates more than $1.8 billion of annual revenue. For more information, visit www.catalent.com.
Contact Details: Dan Dunlop, President & CEO
104-A North Elliott Road
Chapel Hill, NC 27514
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum